Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Part D premiums rise 24 percent
The pharma friend that is Medicare Part D will be more expensive for seniors next year. On average, premiums for the 10 most popular drug-coverage plans will leap by 31 percent. And for all standalone drug plans, the average price hike amounts to 24 percent, to $37 monthly. Meanwhile, Center for Medicare Services chief Kerry Weems is warning that plans may have made "significant" changes in coverage, and he urges seniors to carefully scrutinize their drug plans.
One area that Weems pointed out was drug coverage during the "gap"--the so-called donut hole where benefits drop off once seniors have spent $2,510 on meds. Beneficiaries can buy extra coverage to span the gap, but at an additional cost, of course.
Health plans are blaming their own inaccurate forecasting for increased premiums and coverage cuts. "If [premium] prices are increasing more on the midlevel plans, it's simply because our experience tells us that's where we need to be--premium-wise--to cover our actual costs plus a small margin," a Humana spokesman said. And UnitedHealth Group blamed high Medicare drug costs for its poor earnings this year.
- see the story at WebMD
- read the Wall Street Journal's article
Related Articles:
Part D 'windfall' for pharma, report says
Medicare overpays for new generics
Obama, McCain united against drug costs
Medicare program helps slow rate of drug spending (Feb 2007)
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


